Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Levels of Cytokines Differ Between Sexes With PAH, Study Suggests

The levels of blood-circulating inflammatory molecules differ between men and women with pulmonary arterial hypertension (PAH) and correlate with disease severity, a study suggests. Notably, the levels of two proteins — called IL-6 and MIP-1alpha — were predictors of poorer survival statistics. These findings suggest that patient stratification may…

Yutrepia, Inhaled Treprostinil for PAH, Given Tentative Approval in US

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Yutrepia (treprostinil), previously known as LIQ861, as an inhalation treatment for pulmonary arterial hypertension (PAH), its developer Liquidia announced. Tentative approval means that Yutrepia has met all regulatory standards regarding quality, safety, and efficacy required for approval in the U.S. Because…

Home-based Exercise Can Be Viable Alternative in PAH

A six-month at-home rehabilitation program can help improve respiratory muscle strength and physical endurance, while promoting better quality of life, in people with pulmonary arterial hypertension (PAH) That finding from a small clinical trial revealed benefits extending to six months after the end of the program, and suggests this…

PulmoSIM Planning to Bring PAH Therapy, PT001, Into Clinical Testing

PulmoSIM Therapeutics has joined with scientists at National Jewish Health hospital and Brown University to advance PT001, its investigational and potentially disease-modifying therapy for pulmonary arterial hypertension (PAH), into clinical trials. The partnership follows PT001 being designated an orphan drug by the U.S. Food and Drug Administration (FDA). Orphan drug status…